Biotechnology major, Biocon, said it has received a total of eight observations from the US health regulator for its two new biologics manufacturing facilities in Bengaluru.
The United States Food and Drug Administration (USFDA) conducted a pre-approval inspection (PAI) at two of the company’s new biologics manufacturing facilities in Bengaluru from September 10-19, 2019, Biocon said in a filing to the stock exchange. The inspection included a new drug substance and a drug product unit, it added.
“At the conclusion of the inspection, we received a Form 483 with four observations for the new drug substance facility, three observations for the new drug product facility and one general observation,” a Biocon spokesperson said in a statement. The company is confident of addressing these observations effectively through a Corrective and Preventive Action (CAPA) plan, expeditiously, it added.
The company did not provide any details about the observations made by the US regulator.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Counting the R&D investment of international pharmaceutical giants
What is the food and beverage industry talking about sustainable development?
The latest trend of fragrance notes in epidemic situation
China's imitation stone painting industry ranks first in the world
Global epidemic rebounds, oil demand will be reduced by 2.5 million barrels/day
Teijin develops highly stretchable fibers from plants and renewable raw material